SEC Form 4 · accession 0001779359-26-000004
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Ross Carter
Officer — Chief Financial Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 8, 2026 · 4:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001636651
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 6, 2026 | A | 50,000 | $0.00 | A | 94,375 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date.
- F2Each RSU represents a contingent right to receive one share of Common Stock.